A powerful new agonist: flooding the system with growth hormone.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 20150938.
- Also identified by DOI 10.1038/ki.2009.487.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Niemczyk et al. treated predialysis chronic kidney disease patients with a new growth hormone-releasing hormone agonist, AKL-0707, and noted important changes in body composition characterized by an increase in fat-free mass, a modest rise in bone mineral content, and a reduction in fat mass. These changes were accompanied by a reduction in both serum urea nitrogen and normalized protein nitrogen appearance rate, while dietary protein intake was unchanged. Importantly, there were no serious adverse events.
Medical subject headings
- Growth Hormone-Releasing Hormone
- Human Growth Hormone